Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have received a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $6.25.
Several equities research analysts have recently commented on CPRX shares. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st. BidaskClub cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 7th. Piper Jaffray Companies set a $8.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 1st. SunTrust Banks reissued a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Wednesday, November 29th. Finally, Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st.
Institutional investors have recently made changes to their positions in the stock. Emerald Advisers Inc. PA acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $5,364,000. Teachers Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth $350,000. Vanguard Group Inc. grew its stake in shares of Catalyst Pharmaceuticals by 11.3% during the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock worth $9,242,000 after purchasing an additional 340,614 shares during the period. OxFORD Asset Management LLP grew its stake in shares of Catalyst Pharmaceuticals by 60.5% during the third quarter. OxFORD Asset Management LLP now owns 138,329 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 52,161 shares during the period. Finally, Crestline Management LP acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $562,000. 39.98% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Brokerages Set Catalyst Pharmaceuticals Inc (CPRX) Price Target at $6.25” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2018/02/26/brokerages-set-catalyst-pharmaceuticals-inc-cprx-price-target-at-6-25.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.